Skip to main content

Table 1 Characteristics of the clinical trials included in the meta-analysis

From: The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis

Study Geographic locale Study design Sample size(female/male) Age in years (mean ± SD) HCV-RNA, copies/mL (mean ± SD) HCV genotype 1/non-genotype 1 HBV-DNA, copies/mL (mea ± SD) ALT, U/L (mean ± SD) IFN plus ribavirin regimen
          Drugs Course, weeks Follow-up, weeks
Yu et al. [35] China Cohort C: 10/40 44.9 ± 9.6 5.9 ± 1.4log10 C: 30/20 4.6 ± 0.9log10 97 ± 19 PegIFN-α2a, ribavirin genotype 1: 48 non-genotype 1: 24 24
    M: 9/37 46.4 ± 11.3 6.3 ± 1.3log10 M: 25/21   93 ± 18    
Liu et al. [32] Taiwan Cohort C: 56/105 51.1 ± 10.3 2.16 ± 3.4 × 106 C: 97/64 UD-4.22 × 105 121.0 ± 85.0 PegIFN-α2a, ribavirin genotype 1: 48 non-genotype 1: 24 24
    M: 71/89 48.9 ± 10.5 2.29 ± 4.1 × 105 M: 110/50   126.1 ± 81.8    
Chuang et al. [34] Taiwan Cohort C: 11/31 45.04 ± 10.7 5.38 ± 0.96log10 C: 21/21 2.64 ± 2.26log10 92.1 ± 73.0 IFN-α2b 24 24
    M: 22/62 44.9 ± 11.2 5.60 ± 0.94log10 M: 48/36   141.1 ± 105.5    
Hung et al. [30] Taiwan Cohort C: 14/22 48.8 ± 12.6 5.80 ± 1.10og10 C: 17/19 NR 125.8 ± 89.3 IFN-α2b 24 24
    M: 28/44 48.3 ± 12.0 5.80 ± 1.10og10 M: 34/38   164.2 ± 139.9    
Liu et al. [36] Taiwan Cohort C: 5/19 46.5 ± 13.2 2.4 ± 3.1 × 106 C: 14/7 1.3 ± 2.5 × 103 137.0 ± 81.0 IFN-α2a 24 24
    M: 12/18 48.5 ± 9.4 1.9 ± 2.2 × 106 M: 17/13   177.0 ± 192.0    
  1. C HBV and HCV coinfection, M HCV mono-infection, NR not reported, UD not detectable by the real-time PCR assay.